Kimberly J Van Zee

List of Publications by Year
in descending order

169	11,357	23567 58	31849 101
papers	citations	h-index	g-index

171	171	171	8382
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy. Annals of Surgical Oncology, 2003, 10, 1140-1151.	1.5	747
2	Prevalence of Lymphedema in Women With Breast Cancer 5 Years After Sentinel Lymph Node Biopsy or Axillary Dissection: Objective Measurements. Journal of Clinical Oncology, 2008, 26, 5213-5219.	1.6	530
3	A 14-Year Retrospective Review of Angiosarcoma. Cancer Journal (Sudbury, Mass), 2005, 11, 241-247.	2.0	350
4	Sentinel Lymph Node Biopsy: Is It Indicated in Patients With High-Risk Ductal Carcinoma-In-Situ and Ductal Carcinoma-In-Situ With Microinvasion?. Annals of Surgical Oncology, 2000, 7, 636-642.	1.5	304
5	MR Imaging Findings in the Contralateral Breast of Women with Recently Diagnosed Breast Cancer. American Journal of Roentgenology, 2003, 180, 333-341.	2.2	287
6	Doctor, What Are My Chances of Having a Positive Sentinel Node? A Validated Nomogram for Risk Estimation. Journal of Clinical Oncology, 2007, 25, 3670-3679.	1.6	283
7	Nomogram for Predicting the Risk of Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2010, 28, 3762-3769.	1.6	283
8	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Annals of Surgical Oncology, 2016, 23, 3467-3474.	1.5	232
9	Predicting Nonsentinel Node Status After Positive Sentinel Lymph Biopsy for Breast Cancer: Clinicians Versus Nomogram. Annals of Surgical Oncology, 2005, 12, 654-659.	1.5	211
10	Society of Surgical Oncologyâ€“American Society for Radiation Oncologyâ€“American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2016, 34, 4040-4046.	1.6	211
11	Clinicopathologic Features and Long-Term Outcomes of 293 Phyllodes Tumors of the Breast. Annals of Surgical Oncology, 2007, 14, 2961-2970.	1.5	203
12	Isosulfan Blue Dye Reactions During Sentinel Lymph Node Mapping for Breast Cancer. Anesthesia and Analgesia, 2002, 95, 385-388.	2.2	196
13	Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial. Breast Cancer Research and Treatment, 2001, 66, 239-248.	2.5	189
14	Prevalence of Lymphedema in Women With Breast Cancer 5 Years After Sentinel Lymph Node Biopsy or Axillary Dissection: Patient Perceptions and Precautionary Behaviors. Journal of Clinical Oncology, 2008, 26, 5220-5226.	1.6	187
15	Society of Surgical Oncologyâ€“American Society for Radiation Oncologyâ€“American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. Annals of Surgical Oncology, 2016, 23, 3801-3810.	1.5	176
16	The Impact of Postmastectomy Radiotherapy on Two-Stage Implant Breast Reconstruction. Plastic and Reconstructive Surgery, 2014, 134, 588-595.	1.4	172
17	Stage IV breast cancer in the era of targeted therapy. Cancer, 2010, 116, 1226-1233.	4.1	165
18	Issues of Regret in Women With Contralateral Prophylactic Mastectomies. Annals of Surgical Oncology, 1999, 6, 546-552.	1.5	162

#	Article	IF	Citations
19	Magnetic Resonance Imaging Facilitates Breast Conservation for Occult Breast Cancer. Annals of Surgical Oncology, 2000, 7, 411-415.	1.5	162
20	Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. European Journal of Immunology, 1993, 23, 1889-1894.	2.9	148
21	Society of Surgical Oncologyâ€“American Society for Radiation Oncologyâ€“American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. Practical Radiation Oncology, 2016, 6, 287-295.	2.1	135
22	Fast MRI-Guided Vacuum-Assisted Breast Biopsy:Initial Experience. American Journal of Roentgenology, 2003, 181, 1283-1293.	2.2	134
23	Predictors of intrusive thoughts and avoidance in women with family histories of breast cancer. Annals of Behavioral Medicine, 1997, 19, 362-369.	2.9	131
24	The Accuracy of Sentinel Lymph Node Biopsy in Multicentric and Multifocal Invasive Breast Cancers. Journal of the American College of Surgeons, 2003, 197, 529-535.	0.5	127
25	Incidence and time course of bleeding after longâ€term amenorrhea after breast cancer treatment. Cancer, 2010, 116, 3102-3111.	4.1	127
26	A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate Nomogram. Annals of Surgery, 2007, 245, 462-468.	4.2	126
27	Sensory morbidity after sentinel lymph node biopsy and axillary dissection: A prospective study of 233 women. Annals of Surgical Oncology, 2002, 9, 654-662.	1.5	122
28	Utility of Breast Magnetic Resonance Imaging in Patients With Occult Primary Breast Cancer. Annals of Surgical Oncology, 2005, 12, 1045-1053.	1.5	121
29	Skin Flap Necrosis After Mastectomy With Reconstruction: A Prospective Study. Annals of Surgical Oncology, 2016, 23, 257-264.	1.5	121
30	Reoperative Sentinel Lymph Node Biopsy. Journal of the American College of Surgeons, 2002, 195, 167-172.	0.5	120
31	Intracystic Papillary Carcinoma of the Breast. American Journal of Surgical Pathology, 2011, 35, 1-14.	3.7	118
32	Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery. , 1999, 86, 1757-1767.		114
33	Longâ€term outcomes in breast cancer patients undergoing immediate 2â€stage expander/implant reconstruction and postmastectomy radiation. Cancer, 2012, 118, 2552-2559.	4.1	113
34	Can the Memorial Sloan-Kettering Cancer Center Nomogram Predict the Likelihood of Nonsentinel Lymph Node Metastases in Breast Cancer Patients in The Netherlands?. Annals of Surgical Oncology, 2005, 12, 1066-1072.	1.5	108
35	Patient regrets after bilateral prophylactic mastectomy. Annals of Surgical Oncology, 1998, 5, 603-606.	1.5	107
36	Evaluation of Pectoralis Major Muscle in Patients with Posterior Breast Tumors on Breast MR Images: Early Experience. Radiology, 2000, 214, 67-72.	7.3	105

#	Article	IF	Citations
37	Desmoid Tumors (Fibromatoses) of the Breast: A 25-Year Experience. Annals of Surgical Oncology, 2008, 15, 274-280.	1.5	104
38	Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy. Annals of Surgical Oncology, 2014, 21, 22-27.	1.5	99
39	Preoperative galactography increases the diagnostic yield of major duct excision for nipple discharge. , 1998, 82, 1874-1880.		94
40	Isosulfan Blue Dye Reactions During Sentinel Lymph Node Mapping for Breast Cancer. Anesthesia and Analgesia, 2002, 95, 385-388.	2.2	94
41	Preoperative Breast MRI for Early-Stage Breast Cancer: Effect on Surgical and Long-Term Outcomes. American Journal of Roentgenology, 2014, 202, 1376-1382.	2.2	94
42	Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ. Annals of Surgery, 2015, 262, 623-631.	4.2	94
43	Intradermal Isotope Injection: A Highly Accurate Method of Lymphatic Mapping in Breast Carcinoma. Annals of Surgical Oncology, 2001, 8, 20-24.	1.5	90
44	Radioactive Seed Localization Compared to Wire Localization in Breast-Conserving Surgery: Initial 6-Month Experience. Annals of Surgical Oncology, 2013, 20, 4121-4127.	1.5	90
45	Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers. Annals of Surgery, 2017, 266, 457-462.	4.2	90
46	Bracketing Wires for Preoperative Breast Needle Localization. American Journal of Roentgenology, 2001, 177, 565-572.	2.2	89
47	Comprehensive review of the management of internal mammary lymph node metastases in breast cancer 1 1No competing interests declared.. Journal of the American College of Surgeons, 2001, 193, 547-555.	0.5	84
48	MRI Identifies Otherwise Occult Disease in Select Patients with Paget Disease of the Nipple. Journal of the American College of Surgeons, 2008, 206, 316-321.	0.5	77
49	MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer. Journal of the American College of Surgeons, 2017, 225, 740-746.	0.5	77
50	Morbidity of Sentinel Node Biopsy in Breast Cancer: The Relationship Between the Number of Excised Lymph Nodes and Lymphedema. Annals of Surgical Oncology, 2010, 17, 3278-3286.	1.5	76
51	Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. Journal of the National Cancer Institute, 2014, 106, .	6.3	73
52	Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer11No competing interests declared.. Journal of the American College of Surgeons, 2000, 191, 593-599.	0.5	72
53	Age-related longitudinal changes in depressive symptoms following breast cancer diagnosis and treatment. Breast Cancer Research and Treatment, 2013, 139, 199-206.	2.5	69
54	A Prospective Analysis of the Effect of Blue-Dye Volume on Sentinel Lymph Node Mapping Success and Incidence of Allergic Reaction in Patients With Breast Cancer. Annals of Surgical Oncology, 2004, 11, 535-541.	1.5	67

#	Article	IF	Citations
55	Outcomes for Women With Ductal Carcinoma-in-Situ and a Positive Sentinel Node: A Multi-Institutional Audit. Annals of Surgical Oncology, 2007, 14, 2911-2917.	1.5	66
56	Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?. Annals of Surgical Oncology, 2016, 23, 3487-3493.	1.5	66
57	Controversies in the Treatment of Ductal Carcinoma in Situ. Annual Review of Medicine, 2017, 68, 197-211.	12.2	66
58	Trajectories of Posttraumatic Growth and Associated Characteristics in Women with Breast Cancer. Annals of Behavioral Medicine, 2015, 49, 650-659.	2.9	65
59	Acupuncture in the treatment of upperâ€limb lymphedema. Cancer, 2013, 119, 2455-2461.	4.1	64
60	Chest wall resection for locally recurrent breast cancer: Is it worthwhile?. Journal of Thoracic and Cardiovascular Surgery, 2000, 119, 420-428.	0.8	61
61	Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. Annals of Surgical Oncology, 2017, 24, 375-397.	1.5	61
62	Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapyâ€"A Rare Event. JAMA Oncology, 2021, 7, 1851.	7.1	61
63	Validation of a Nomogram to Predict the Risk of Nonsentinel Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Node Biopsy: Validation of the MSKCC Breast Nomogram. Annals of Surgical Oncology, 2009, 16, 1128-1135.	1.5	60
64	Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma. Annals of Surgical Oncology, 1998, 5, 23-27.	1.5	56
65	Explaining age-related differences in depression following breast cancer diagnosis and treatment. Breast Cancer Research and Treatment, 2012, 136, 581-591.	2.5	55
66	Mastectomy With Immediate Expander-Implant Reconstruction, Adjuvant Chemotherapy, and Radiation for Stage IIâ€"III Breast Cancer: Treatment Intervals and Clinical Outcomes. International Journal of Radiation Oncology Biology Physics, 2008, 70, 43-50.	0.8	51
67	Eighteen Sensations After Breast Cancer Surgery: A 5-Year Comparison of Sentinel Lymph Node Biopsy and Axillary Lymph Node Dissection. Annals of Surgical Oncology, 2007, 14, 1653-1661.	1.5	50
68	Perioperative Breast MRI Is Not Associated with Lower Locoregional Recurrence Rates in DCIS Patients Treated With or Without Radiation. Annals of Surgical Oncology, 2014, 21, 1552-1560.	1.5	50
69	Postmastectomy intensity modulated radiation therapy following immediate expander-implant reconstruction. Radiotherapy and Oncology, 2010, 94, 319-323.	0.6	49
70	Local Relapse After Breast-Conserving Therapy for Ductal Carcinoma In Situ. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.6	49
71	Morbidity of Sentinel Node Biopsy: Relationship Between Number of Excised Lymph Nodes and Patient Perceptions of Lymphedema. Annals of Surgical Oncology, 2011, 18, 2866-2872.	1.5	48
72	Perpendicular Inked Versus Tangential Shaved Margins in Breast-Conserving Surgery: Does the Method Matter?. Journal of the American College of Surgeons, 2007, 204, 541-549.	0.5	47

#	Article	IF	Citations
73	Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Annals of Surgical Oncology, 2015, 22, 3273-3281.	1.5	46
74	Trajectories of Depressive Symptoms Following Breast Cancer Diagnosis. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1789-1795.	2.5	45
75	Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene, 1998, 16, 2723-2727.	5.9	43
76	Eighteen Sensations After Breast Cancer Surgery: A Comparison of Sentinel Lymph Node Biopsy and Axillary Lymph Node Dissection. Oncology Nursing Forum, 2002, 29, 651-659.	1.2	43
77	Sentinel Lymph Node Drainage in Multicentric Breast Cancers. Breast Journal, 2002, 8, 356-361.	1.0	43
78	A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. Cancer, 2004, 101, 2509-2515.	4.1	42
79	Axillary Node Staging for Microinvasive Breast Cancer: Is It Justified?. Annals of Surgical Oncology, 2012, 19, 3416-3421.	1.5	42
80	One Operation After Percutaneous Diagnosis of Nonpalpable Breast Cancer. American Journal of Roentgenology, 2002, 178, 673-679.	2.2	41
81	The Influence of Margin Width and Volume of Disease Near Margin on Benefit of Radiation Therapy for Women With DCIS Treated With Breast-Conserving Therapy. Annals of Surgery, 2010, 251, 583-591.	4.2	40
82	Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?. Annals of Surgical Oncology, 2016, 23, 4253-4261.	1.5	40
83	A Safety and Efficacy Pilot Study of Acupuncture for the Treatment of Chronic Lymphoedema. Acupuncture in Medicine, 2011, 29, 170-172.	1.0	38
84	Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Annals of Surgical Oncology, 2016, 23, 2816-2824.	1.5	38
85	In microdissected ductal carcinoma in situ, HER-2/neu amplification, but notp53 mutation, is associated with high nuclear grade and comedo histology. Cancer, 2000, 89, 2153-2160.	4.1	37
86	Extent of Microinvasion in Ductal Carcinoma In Situ is not Associated with Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2014, 21, 3330-3335.	1.5	37
87	Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. Cancer, 2018, 124, 46-54.	4.1	37
88	Eighteen Sensations After Breast Cancer Surgery: A Two-Year Comparison of Sentinel Lymph Node Biopsy and Axillary Lymph Node Dissection. Oncology Nursing Forum, 2004, 31, 691-698.	1.2	36
89	Six-Year Follow-Up of Patients With Microinvasive, T1a, and T1b Breast Carcinoma. Annals of Surgical Oncology, 1999, 6, 591-598.	1.5	34
90	Expression of E2F-1 and E2F-4 is reduced in primary and metastatic breast carcinomas*. Breast Cancer Research and Treatment, 2001, 69, 115-122.	2.5	33

#	Article	IF	Citations
91	Reexcision â€" The Other Breast Cancer Epidemic. New England Journal of Medicine, 2015, 373, 568-569.	27.0	33
92	Impact of Margin Assessment Method on Positive Margin Rate and Total Volume Excised. Annals of Surgical Oncology, 2014, 21, 86-92.	1.5	31
93	Fibroepithelial Lesions in the Breast of Adolescent Females: A Clinicopathological Study of 54 Cases. Breast Journal, 2017, 23, 182-192.	1.0	31
94	Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ. International Journal of Surgical Pathology, 2017, 25, 100-107.	0.8	31
95	Comparison of Peripheral Blood Leukocyte Kinetics After Live Escherichia coli, Endotoxin, or Interleukin-1 Î± Administration Studies Using a Novel Interleukin-1 Receptor Antagonist. Annals of Surgery, 1993, 218, 79-90.	4.2	30
96	Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast. Annals of Surgical Oncology, 2019, 26, 2136-2143.	1.5	30
97	Pilot Study of Anti-Th2 Immunotherapy for the Treatment of Breast Cancer-Related Upper Extremity Lymphedema. Biology, 2021, 10, 934.	2.8	30
98	The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock. Journal of Clinical Immunology, 1994, 14, 120-133.	3.8	28
99	Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?. Annals of Surgical Oncology, 2017, 24, 2889-2897.	1.5	28
100	Trajectories of quality of life following breast cancer diagnosis. Breast Cancer Research and Treatment, 2018, 169, 163-173.	2.5	28
101	Papilloma Diagnosed at MRI-Guided Vacuum-Assisted Breast Biopsy: Is Surgical Excision Still Warranted?. American Journal of Roentgenology, 2012, 199, W512-W519.	2.2	27
102	Acupuncture for breast cancer-related lymphedema: a randomized controlled trial. Breast Cancer Research and Treatment, 2018, 170, 77-87.	2.5	27
103	Volume of resection in patients treated with breast conservation for ductal carcinoma in situ. Annals of Surgical Oncology, 1998, 5, 757-763.	1.5	25
104	Tissue Expander Breast Reconstruction is Not Associated with an Increased Risk of Lymphedema. Annals of Surgical Oncology, 2010, 17, 2926-2932.	1.5	25
105	Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2016, 23, 3481-3486.	1.5	25
106	Is It Really Duct Carcinoma In Situ?. Annals of Surgical Oncology, 2001, 8, 617-617.	1.5	23
107	Genetic Alterations of the p14ARF-hdm2-p53 Regulatory Pathway in Breast Carcinoma. Breast Cancer Research and Treatment, 2001, 65, 225-232.	2.5	23
108	Point: Sentinel Lymph Node Biopsy Is Indicated for Patients With DCIS. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 199-206.	4.9	22

#	Article	IF	Citations
109	Oncologic Outcomes After Treatment for MRI Occult Breast Cancer (pT0N+). Annals of Surgical Oncology, 2017, 24, 3141-3147.	1.5	22
110	Minimal Disease in the Sentinel Lymph Node: How to Best Measure Sentinel Node Micrometastases to Predict Risk of Additional Non-Sentinel Lymph Node Disease. Annals of Surgical Oncology, 2010, 17, 2909-2919.	1.5	21
111	Is There a Low-Grade Precursor Pathway in Breast Cancer?. Annals of Surgical Oncology, 2012, 19, 1115-1121.	1.5	20
112	Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients. Annals of Surgical Oncology, 2020, 27, 1617-1624.	1.5	20
113	Can Surgical Oncologists Reliably Predict the Likelihood for Non-SLN Metastases in Breast Cancer Patients?. Annals of Surgical Oncology, 2007, 14, 615-620.	1.5	19
114	Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breastâ€conserving therapy. Cancer, 2009, 115, 1203-1214.	4.1	19
115	Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score. Annals of Surgical Oncology, 2019, 26, 3282-3288.	1.5	19
116	Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion. Annals of Surgical Oncology, 2019, 26, 4264-4271.	1.5	19
117	Ductal carcinoma in situ of the breast: Progress and controversy. Current Problems in Surgery, 1996, 33, 555-600.	1.1	18
118	Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. Cancer Genetics and Cytogenetics, 2001, 125, 131-138.	1.0	18
119	Microsatellite instability in breast cancer. Annals of Surgical Oncology, 1997, 4, 310-315.	1.5	17
120	Minimally invasive breast surgery. Journal of the American College of Surgeons, 2004, 199, 961-975.	0.5	14
121	Predictors of Completion Axillary Lymph Node Dissection in Patients With Immunohistochemical Metastases to the Sentinel Lymph Node in Breast Cancer. Annals of Surgical Oncology, 2010, 17, 1063-1068.	1.5	14
122	Changing the Default: A Prospective Study of Reducing Discharge Opioid Prescription after Lumpectomy and Sentinel Node Biopsy. Annals of Surgical Oncology, 2020, 27, 4637-4642.	1.5	14
123	Validating a Predictive Model for Presence of Additional Disease in the Nonâ€“Sentinel Lymph Nodes of a Woman with Sentinel Node Positive Breast Cancer. Annals of Surgical Oncology, 2007, 14, 2177-2178.	1.5	13
124	The effect of age in the outcome and treatment of older women with ductal carcinoma in situ. Breast, 2011, 20, 71-77.	2.2	13
125	Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. Annals of Surgical Oncology, 2017, 24, 3888-3895.	1.5	13
126	Cosmetic Outcomes Following Breast-Conservation Surgery and Radiation for Multiple Ipsilateral Breast Cancer: Data from the Alliance Z11102 Study. Annals of Surgical Oncology, 2020, 27, 4650-4661.	1.5	13

#	Article	IF	Citations
127	Preoperative galactography increases the diagnostic yield of major duct excision for nipple discharge. Cancer, 1998, 82, 1874-1880.	4.1	12
128	Sensory Morbidity After Sentinel Lymph Node Biopsy and Axillary Dissection: A Prospective Study of 233 Women. Annals of Surgical Oncology, 2002, 9, 654-662.	1.5	12
129	Intraoperative Ketorolac is Associated with Risk of Reoperation After Mastectomy: A Single-Center Examination. Annals of Surgical Oncology, 2021, 28, 5134-5140.	1.5	11
130	Predicting Nonsentinel Node Metastases in Sentinel Node-Positive Breast Cancer: What Have We Learned, Can We Do Better, and Do We Need To?. Annals of Surgical Oncology, 2008, 15, 2998-3002.	1.5	10
131	A SEER-Medicare population-based study of lymphedema-related claims incidence following breast cancer in men. Breast Cancer Research and Treatment, 2011, 130, 301-306.	2.5	10
132	Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens. Annals of Surgical Oncology, 1997, 4, 416-420.	1.5	8
133	Atypical ductal hyperplasia bordering on DCIS on core biopsy is associated with higher risk of upgrade than conventional atypical ductal hyperplasia. Breast Cancer Research and Treatment, 2020, 184, 873-880.	2.5	8
134	Routine Opioid Prescriptions Are Not Necessary After Breast Excisional Biopsy or Lumpectomy Procedures. Annals of Surgical Oncology, 2021, 28, 303-309.	1.5	8
135	Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy. Breast Cancer Research and Treatment, 2021, 186, 617-624.	2.5	8
136	Validation of a Nomogram for Predicting Risk of Local Recurrence for Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2012, 30, 3143-3144.	1.6	7
137	Blurry Boundaries: Do Epithelial Borderline Lesions of the Breast and Ductal Carcinoma In Situ Have Similar Rates of Subsequent Invasive Cancer?. Annals of Surgical Oncology, 2013, 20, 1302-1310.	1.5	7
138	Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncology, 2016, 2, 397.	7.1	7
139	Prevalence and correlates of job and insurance problems among young breast cancer survivors within 18â€‰months of diagnosis. BMC Cancer, 2020, 20, 432.	2.6	7
140	Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ. Annals of Surgical Oncology, 2019, 26, 4317-4325.	1.5	6
141	Intradermal Isotope Injection: A Highly Accurate Method of Lymphatic Mapping in Breast Carcinoma. Annals of Surgical Oncology, 2001, 8, 20-24.	1.5	6
142	Postdischarge Nonsteroidal Anti-Inflammatory Drugs Are not Associated with Risk of Hematoma after Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. Annals of Surgical Oncology, 2021, 28, 5507-5512.	1.5	4
143	Use of Axillary Staging in the Management of Ductal Carcinoma In Situ. JAMA Oncology, 2015, 1, 332.	7.1	3
144	Margins in DCIS: Does Residual Disease Provide an Answer?. Annals of Surgical Oncology, 2016, 23, 3423-3425.	1.5	3

#	Article	IF	Citations
145	Ductal Carcinoma In Situ of the Breast. Advances in Surgery, 2019, 53, 21-35.	1.3	3
146	Reply to: â€œKetorolac Following Mastectomy: Is There an Increased Risk of Reoperation?â€. Annals of Surgical Oncology, 2021, 28, 777-778.	1.5	3
147	Reply to C. Mazouni et al. Journal of Clinical Oncology, 2011, 29, e45-e46.	1.6	2
148	Memorial Sloan-Kettering Cancer Center: Two Decades of Experience with Ductal Carcinoma In Situ of the Breast. International Journal of Surgical Oncology, 2012, 2012, 1-8.	0.6	2
149	Use of Established Nomograms to Predict Non-Sentinel Lymph Node Metastasis. Current Breast Cancer Reports, 2014, 6, 24-31.	1.0	2
150	Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial: A Reply. Annals of Surgical Oncology, 2017, 24, 568-569.	1.5	2
151	Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated with breast-conserving surgery over 30 years.. Journal of Clinical Oncology, 2015, 33, 32-32.	1.6	1
152	Are breast cancer patients at increased risk for colorectal adenomas and cancer: Effect of family history and age. Gastroenterology, 2000, 118, A44.	1.3	0
153	Breast imaging: a breast surgeon's perspective. Radiologic Clinics of North America, 2002, 40, 517-520.	1.8	0
154	Predictive Models: The Art and the Science. Breast Diseases, 2008, 19, 118-119.	0.0	0
155	Are Nomograms for the Prediction of Non-Sentinel Lymph Node Status Obsolete?. Breast Diseases, 2011, 22, 15-17.	0.0	0
156	Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery for Ductal Carcinoma in Situ. Annals of Surgery, 2011, 253, 1233-1234.	4.2	0
157	Reply to U.K. Ballehaninna et al. Journal of Clinical Oncology, 2011, 29, e99-e99.	1.6	0
158	Breast Ductal Carcinoma In Situ. International Journal of Surgical Oncology, 2012, 2012, 1-2.	0.6	0
159	Commentary on the Canadian National Breast Screening Study. Annals of Surgical Oncology, 2014, 21, 4397-4398.	1.5	0
160	ASO Author Reflections: Does Genomic Testing of DCIS Provide Added Value? And Is It Worth the Cost?. Annals of Surgical Oncology, 2019, 26, 702-703.	1.5	0
161	ASO Author Reflections: Advising a Woman with Ductal Carcinoma In Situ Regarding Various Treatment Optionsâ€”A Complex Decision. Annals of Surgical Oncology, 2019, 26, 4272-4273.	1.5	0
162	Treatment of Ductal Carcinoma In Situ: Considerations for Tailoring Therapy in the Contemporary Era. Current Breast Cancer Reports, 2020, 12, 98-106.	1.0	0

#	Article	IF	Citations
163	ASO Visual Abstract: Post-Discharge Non-Steroidal Anti-Inflammatory Drugs Are Not Associated with Risk of Hematoma After Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. Annals of Surgical Oncology, 2021, 28, 635-636.	1.5	0
164	Mri-Guided Needle Localization. , 2005, , 23-27.		0
165	Total Mastectomy. , 2005, , 79-91.		0
166	Abstract 3139: Can PI3K/AKT pathway mutations predict for type of recurrence after conservative treatment for DCIS. , 2011, , .		0
167	A Comparison of Breast Surgeon and Nomogram-Generated Risk Predictions of Sentinel and Non-Sentinel Node Metastases. Journal of Cancer Therapy, 2013, 04, 1-6.	0.4	0
168	Long-term rates of ipsilateral breast tumor recurrence (IBTR) for women with ductal carcinoma in situ (DCIS) meeting LORIS trial eligibility criteria undergoing standard therapy.. Journal of Clinical Oncology, 2015, 33, 560-560.	1.6	0
169	Surgical Treatment of Ductal CarcinomaÂIn Situ. , 2018, , 171-192.		0